New combo therapy shows promise for Tough-to-Treat lymphoma
NCT ID NCT05464329
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 23 times
Summary
This study tests whether adding the drug mosunetuzumab to standard chemotherapy is safe and effective for people with aggressive B-cell lymphoma that has come back or not responded to prior treatment. About 24 adults will receive one of two chemotherapy backbones plus mosunetuzumab. The main goal is to check side effects and see how many patients achieve complete remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.